Mexico: COFECE to probe generic drug market

Mexico’s competition regulator COFECE has announced the start of a thorough market study, aimed at the generic drug market.

The regulator said it is concerned with finding out why, out of approximately 350 “single source” medicines obtained by the Public Health sector through direct no-contest contracts, up to 63% are not patent-protected. However, despite this lack of protection, no rival makers have appeared to challenge these products’ sole manufacturers or distributors.

“International evidence indicates that, when a patent on an innovative medication run out, the arrival of several ‘generics’ makers is a boon to competition, translating into lower prices and a greater range of options for consumers” said the COFECE.

After conducting their investigation, the agency is expected to make a series of recommendations and proposals aimed at improving free competition in this market, including any necessary sanctions or remedies to correct failings in the market.

Full Content: América Economía

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.